Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
Executive Summary
Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy
You may also be interested in...
FDA panel to review Solvay cilansetron
FDA's Gastrointestinal Drugs and Drug Safety & Risk Management Advisory Committees are expected to discuss Solvay's NDA for the irritable bowel syndrome treatment cilansetron at a joint meeting, the company says. The committees are tentatively scheduled to meet jointly on March 9. FDA has extended its review of cilansetron by 90 days to April 1, 2005; the proposed trade name for the drug is Calmactin (1"The Pink Sheet" May 24, 2004, p. 32)...
FDA panel to review Solvay cilansetron
FDA's Gastrointestinal Drugs and Drug Safety & Risk Management Advisory Committees are expected to discuss Solvay's NDA for the irritable bowel syndrome treatment cilansetron at a joint meeting, the company says. The committees are tentatively scheduled to meet jointly on March 9. FDA has extended its review of cilansetron by 90 days to April 1, 2005; the proposed trade name for the drug is Calmactin (1"The Pink Sheet" May 24, 2004, p. 32)...
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies